LB Pharmaceuticals Inc
LBRX
$47.78
$3.517.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 241.94% | 147.97% | -3.41% | -47.83% | 23.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 882.53% | 242.26% | 134.16% | -67.38% | -80.08% |
| Operating Income | -882.53% | -242.26% | -134.16% | 67.38% | 80.08% |
| Income Before Tax | -914.11% | -259.10% | -126.25% | 74.92% | 81.63% |
| Income Tax Expenses | -- | -- | 0.00% | -- | -- |
| Earnings from Continuing Operations | -914.11% | -259.10% | -126.23% | 74.92% | 81.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -914.11% | -259.10% | -126.23% | 74.92% | 81.63% |
| EBIT | -882.53% | -242.26% | -134.16% | 67.38% | 80.08% |
| EBITDA | -895.27% | -245.23% | -136.03% | 67.88% | 80.37% |
| EPS Basic | 91.53% | 95.44% | 96.80% | 98.45% | 68.77% |
| Normalized Basic EPS | 91.35% | 95.56% | 97.25% | 98.50% | -- |
| EPS Diluted | 91.53% | 95.44% | 96.80% | 98.45% | 68.77% |
| Normalized Diluted EPS | 91.35% | 95.56% | 97.25% | 98.50% | -- |
| Average Basic Shares Outstanding | 11,868.90% | 7,771.15% | 6,972.97% | 1,517.07% | -- |
| Average Diluted Shares Outstanding | 11,868.90% | 7,771.15% | 6,972.97% | 1,517.07% | 0.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |